Details for Patent: 6,506,405

United States Patent 6,506,405: Scope, Claim Architecture, and Practical Patent-Landscape Implications

What does US 6,506,405 claim in plain scope terms?

US 6,506,405 is a broad “formulation + dosing regimen” family centered on taxanes (explicitly paclitaxel and docetaxel) delivered in non-cremophor systems, with tight control of dose, infusion time, cycle length, and regimen requirements. The claims repeatedly tie performance to: (i) avoidance of cremophor and/or surfactants, (ii) reduced hypersensitivity and reduced neurologic toxicity, (iii) stability and practical handling (reconstitution, storage, device compatibility), and (iv) therapeutic targeting via “high local concentration” at tumors and specified tumor types/sites.

At the highest level, the claim set clusters into four enforceable pillars:

1. Composition claims: paclitaxel formulations substantially free of cremophor (and later, “substantially free of surfactants”).
2. Unit dosage/article-of-manufacture claims: sealed vials/vessels and lyophilized taxane that are cremophor-free/surfactant-free, with performance proxies like stability windows and device compatibility.
3. Method of administration claims (taxane/paclitaxel/docetaxel): systemic dosing without premedication, with infusion time and regimen constraints (cycle length up to 3 weeks, administration period thresholds like 3 hours, 2 hours, 1 hour).
4. Therapeutic-use claims: treating primary tumors and metastatic tumors via “high local concentration at the tumor site/site of metastases,” plus targeted indications and specific prostatic interventions (medical orchiectomy).

How are the claims structured and where is the real breadth?

The text you provided is a claim listing (1–89) with many dependent variations. The breadth comes less from the single independent claim and more from how dependent claims broaden the same core theme across:

• Drug coverage: paclitaxel and docetaxel (and sometimes “taxane” generically).
• Vehicle exclusions: cremophor exclusion is primary; later claims swap to “surfactants” exclusion.
• Administration constraints: dose range (30–1000 mg/m2), infusion time (<= 3 hours and lower cutoffs), cycle length (<= 3 weeks and <= 2 weeks), and “no premedication.”
• Clinical outcomes: reduced cerebral/neurologic toxicity and reduced hematologic toxicity requiring no recovery agents.
• Product handling: stability after aqueous diluent addition, stability during refrigeration, ability to use standard infusion sets, lyophilized form and reconstitution concentration.

A practical read: if a competitor product is a cremophor-free (or surfactant-free) taxane presentation that can be dosed within these parameter bands and is marketed/used for these regimen constructs, it faces direct infringement exposure on multiple claim categories simultaneously.

What are the core claim elements (recurring limitations)?

Across the claims, the same limitations recur with minimal variation:

1) Substantially free of cremophor (and sometimes surfactants)

• “substantially free of cremophor” is explicitly in Claims 1, 2, 6, 10, 13, 27, 30, 33, 37, 41, 44, 48, 50, 60, 65, and multiple others.
• “free of cremophor” appears in dependent positions like 2, 11, 14, 31, 34, 36, 38, 42, 43.
• “substantially free of surfactants” appears in Claims 65–66, 67–72, 80–82 and method language in 69–70 and 80.

Implication: design-around must address both “cremophor” and, depending on claim coverage, “surfactants” broadly. A formulation that swaps cremophor for another surfactant may still land in the “surfactant-free” branch.

2) Dose band (30–1000 mg/m2)

Repeated in nearly every major claim:

• Formulation and unit dose: 30 mg/m2 to 1000 mg/m2 (e.g., Claims 1, 10, 13, 41, 44, 50, 54–57, 60–64, 65–66, 73).
• Numerous dependent bands tighten the range (examples):
  • 50–800 mg/m2 with administration period <= 3 hours (6)
  • 70–400 mg/m2 (7, 9, 62, 64, 77 and others)
  • 80–700 mg/m2 with cycle <= 3 weeks (8)
  • 135 mg/m2+, 175 mg/m2+, 250 mg/m2+ in method claims (19–21)
  • >80 mg/m2 and up to 700 mg/m2 (22)
  • Several docetaxel/taxane methods repeat the same structure (45–47, 48–49).

Implication: even if competitors use standard clinical dosing that falls within common taxane ranges, they may still fall into the claim band if vehicle and time/cycle constraints match.

3) Infusion/administration window

Core thresholds:

• “administration period of no greater than about 3 hours” (6, 10, 15, 23 and 46)
• dependent cutoffs:
  • “less than about 2 hours” (16)
  • “less than about 1 hour” (17)
• multiple general methods use “no greater than about 3 hours” for taxane; docetaxel has an alternate higher ceiling in one method set:
  • “administration period no greater than about 13 hours” (47)
  • taxane versions keep the 3-hour cap (46, 69, 70)

Implication: the narrower the administration window claim is, the more it becomes dependent on actual clinical protocol. But the existence of claims with both 3-hour and 13-hour style caps for docetaxel means competitors cannot rely on standard docetaxel infusion duration if it lands inside that “<= 13 hours” band while also satisfying the cremophor-free and dosing limitations.

4) Cycle length

• “treatment cycle of no greater than about 3 weeks” (8, 44, 45, 67–68, 73?)
• “treatment cycle no greater than about 2 weeks” (25)
• dosage regimen coupling appears repeatedly in the “method” claims.

Implication: regimen design must consider more than dosing speed; schedule length matters.

5) Premedication and hematologic recovery agent exclusions

• “without the use of premedication” appears in the main method claim:
  • 13
• “does not require use of agents which aid in the recovery from hematologic toxicity of paclitaxel” appears in:
  • 18
• taxane method:
  • 48 similarly excludes hematologic recovery agents for paclitaxel-like structure.
• docetaxel method language mirrors:
  • 49 excludes hematologic recovery agents and adds a “substantially free of surfactants” condition.

Implication: if the clinical protocol includes standard premedication (commonly used for taxanes to manage hypersensitivity), the claim set’s “no premedication” limitation can become a key trigger for non-infringement. But the claims also include reduced hypersensitivity without explicitly forcing “no premedication” for all paths, so infringement risk can persist depending on claim pathway and how product is used in practice.

6) Outcomes: hypersensitivity, cerebral/neurologic toxicity, hematologic toxicity

• “reduced cerebral or neurologic toxicity” (5)
• reduced incidence of hypersensitivity:
  • for paclitaxel: 60
  • for taxane unit dosage: 61, 71
  • for docetaxel: 63, 72
  • for article-of-manufacture versions: 76, 78–83 (and other repetitions)
• “reducing hematologic toxicity”:
  • 27
• “reducing cerebral or neurologic toxicity”:
  • 30

Implication: the patent ties vehicle changes to safety outcomes. In litigation, proving performance (reduced toxicity vs baseline cremophor formulations) can matter if construed as product-by-process or functional limitations.

7) Tumor targeting: “high local concentration”

• Primary tumors:
  • 1 (paclitaxel; formulation achieving “high local concentration at tumor site”)
  • 33 (method: achieving “high local concentration”)
  • 35 (tumor list)
  • 54–55 (unit dosage for primary tumor treatment)
• Metastatic tumors:
  • 37 (method: achieving “high local concentration” at metastasis site)
  • 39 (metastasis site list)
  • 56–57 (unit dosage for metastatic tumor treatment)

Implication: if a competitor argues systemic paclitaxel distribution instead of “local concentration at tumor site,” infringement may turn on claim construction of the functional phrase.

What is covered for indications and tumor sites?

Primary tumors (explicit tumor list)

• Cancers of prostate, testes, lung, kidney, pancreas, bone, spleen, liver or brain appear as a tumor selection in:
  • 3 (formulation claim)
  • 35 (method claim)

Metastatic tumors (site list)

• Sites selected from lung, bone, liver or brain appear in:
  • 39

Prostate-specific interventional construct

• “thereby inducing a medical orchiectomy” appears in:
  • 41–43

Implication: the claim set is not limited to oncology generally; it includes specific tumor types and a prostate-focused mechanistic clinical endpoint.

What do the formulation and unit-dosage claims look like as enforceable product scope?

Paclitaxel formulation without cremophor (and later surfactants)

• Claim 1: paclitaxel formulation; “treatment of primary tumors”; “high local concentration”; substantially free of cremophor; dose 30–1000 mg/m2
• Claim 65: similar concept but “substantially free of surfactants”

Unit dosage form with systemic dosing within infusion and vehicle constraints

• Claim 10: unit dosage form in a vessel; non-aqueous formulation; substantially free of cremophor; dose 30–1000 mg/m2; administration over “less than 3 hours”
• Claim 66: similar but “substantially free of surfactants”
• Additional product-handling constraints appear later, including:
  • stability after aqueous diluent addition:
  • 50–51 for taxane/docetaxel: stable “> 24 hours and < 3 days”
  • refrigeration stability not adversely affecting:
  • 52–53
  • plasticizer leach avoidance from devices:
  • 58–59
  • reduced incidence of hypersensitivity vs cremophor:
  • 60–64, 71–72, 76–83
  • lyophilized taxane:
  • 84–89, including reconstitution concentration and stability windows:
    • ability to be reconstituted at concentrations “greater than 1.3 mg/ml” and remain stable “at least 3 days” (86, 88)
    • “administered in standard infusion sets” (87, 89)

Implication: the patent is not only about “no cremophor.” It extends into practical manufacturing and use conditions that can be hard to fully redesign around while keeping comparable administration convenience.

What dosing/regimen methods are directly claimed?

Paclitaxel method (no premedication)

• Claim 13: systemically administer paclitaxel dose 30–1000 mg/m2 in cremophor-free formulation; no premedication
• dependent refinements:
  • cremophor-free (14)
  • infusion period < 3 hours (15)
  • < 2 hours (16)
  • < 1 hour (17)
  • no recovery agents for hematologic toxicity (18)
  • dose escalation thresholds (19–21)
  • dose >80 to 700 (22)
  • bolus injection path (23–24)
  • cycle length <= 2 weeks (25)
  • dose >= 50 mg/m2 (26)

Hematologic and neurologic toxicity reduction methods (paclitaxel)

• Claim 27: reduce hematologic toxicity via cremophor-free paclitaxel formulation at 30–1000 mg/m2
• Claim 30: reduce cerebral/neurologic toxicity via cremophor-free paclitaxel formulation at 30–1000 mg/m2
• dependent adds albumin and cremophor-free constraints:
  • 28–29
  • 31–32

Treatment methods for primary and metastatic tumors

• Claim 33: treat primary tumors by achieving high local concentration; dose 30–1000 mg/m2; cremophor-free formulation
• Claim 37: treat metastatic tumors by achieving high local concentration; dose 30–1000 mg/m2; cremophor-free formulation
• dependent constraints:
  • tumor selections (35)
  • metastasis site selections (39)
  • albumin inclusion (36, 40)

Taxane general method (cycle and infusion caps) and docetaxel variants

• Claim 44: taxane administration (dose 30–1000 mg/m2, cycle <= 3 weeks, substantially free of cremophor)
• Claim 45: docetaxel administration version with same parameter set
• Claim 46: taxane method with administration period <= 3 hours
• Claim 47: docetaxel method with administration period <= 13 hours

Surfactant-free branch and hypersensitivity reduction

• Claims 48–49: admin paclitaxel/docetaxel without hematologic toxicity recovery agents; paclitaxel uses cremophor-free; docetaxel uses surfactant-free language.
• Claims 50–53: stability of unit dosage post-dilution/refrigeration.
• Claims 67–70: surfactant-free taxane/docetaxel methods; cycle and infusion constraints.
• Claims 71–72: unit dosage forms conferring reduced hypersensitivity vs surfactant-containing formulations.

What does the “albumin” dependency change in scope?

Albumin inclusion appears as a dependent option:

• paclitaxel formulation:
  • 4 and 36
• toxicity reduction method:
  • 29 and 32
• It does not replace the core vehicle exclusion; it adds an additional composition feature.

Implication: an accused product that is cremophor-free but does not include albumin could avoid albumin-specific dependent claims, but independent limitations still remain.

Key claim-risk matrix for competitors (based solely on provided claim text)

The table maps the most common competitor design parameters to the claim hotspots.

What does this mean for the patent landscape (scope vs likely overlaps)?

Your claim text signals a landscape where multiple generations of taxane formulation patents exist, but 6,506,405 is positioned to be both:

• Vehicle-centric (cremophor/surfactant avoidance)
• Regimen-centric (no premedication; infusion time; cycle length)
• Product-form factor centric (vessel/ sealed vial; lyophilized handling; infusion set compatibility)

Practical landscape effect (how it blocks freedom-to-operate)

Even without evaluating priority dates of other patents, the internal claim breadth suggests a product will typically need to change at least one of the following to create meaningful freedom-to-operate:

• avoid not only cremophor, but also surfactants if competing claims are asserted;
• use a dosing regimen outside the explicitly claimed infusion time/cycle/dose bands;
• incorporate premedication if the relevant method claim pathway requires “without premedication”;
• alter product-handling characteristics if asserting against lyophilized or stability/device-compatibility dependent claims.

Where “design-around” is hardest

The hardest-to-avoid components are those that appear as:

• broad dose bands (30–1000 mg/m2),
• broad infusion ceilings (<=3 hours for taxane),
• broad vehicle exclusions (substantially free of cremophor),
• and broad unit dosage constructs (sealed vial/vessel suitable for systemic administration).

Those limitations together create a wide net for any cremophor-free taxane approach that is dosed fast and administered in standard formats.

Patent architecture: independent vs dependent claim density

The claim list shows extensive dependent layering. Examples:

• Infusion time has three descending cutoffs in the paclitaxel method claim chain (15–17).
• Dose has stepwise thresholds and alternative bands (19–22).
• Treatment cycle has explicit caps (8, 25, 44–45, 67–68).
• Safety exclusions mirror across toxicity and hypersensitivity outcomes (18, 27, 30, 60–64).

This density matters for enforcement strategy: the patent can be asserted with a smaller set of facts if a key dependent feature matches, even if the full independent combination is contested.

Key Takeaways

• US 6,506,405 claims cremophor-free taxane formulations and regimens with dose band 30–1000 mg/m2, repeated across paclitaxel and docetaxel.
• The patent’s enforcement leverage is the combination of vehicle exclusion (cremophor and sometimes surfactants), administration constraints (commonly <= 3 hours for taxane; <= 13 hours for docetaxel), and regimen constructs (cycle <= 3 weeks; sometimes <= 2 weeks; paclitaxel “without premedication”).
• Product form and usability limitations extend scope to sealed vials, non-aqueous formulations, plasticizer-leach avoidance, reconstitution stability windows, refrigeration stability, and lyophilized taxane with >1.3 mg/ml reconstitution and >=3-day stability.
• Indication coverage is present through primary tumor and metastatic tumor targeting via “high local concentration,” plus a specific prostate construct (“medical orchiectomy”).

FAQs

1. Does US 6,506,405 cover both paclitaxel and docetaxel?
   Yes. The claim set includes paclitaxel formulation and methods, docetaxel methods, and also generic “taxane” administration and unit dosage language (e.g., 44–48, 45–47, 50–53, 63–64, 84–89).

2. Is “no cremophor” the only formulation requirement?
   No. The claims also contain “substantially free of surfactants” language and multiple functional/handling constraints such as stability after reconstitution and infusion set compatibility (e.g., 49, 65–66, 69–70, 84–89).

3. What infusion timing is most central to infringement risk?
   The taxane tracks repeatedly use <= 3 hours and also include shorter thresholds for paclitaxel methods (<2 hours and <1 hour). Docetaxel includes a method cap of <= 13 hours (e.g., 15–17, 46–47).

4. Do any method claims require avoiding premedication?
   Yes. Paclitaxel administration method claim language requires administration “without the use of premedication” (Claim 13).

5. Do claims extend beyond “formulation” into product handling?
   Yes. There are explicit unit dosage and article-of-manufacture claims tied to stability windows after aqueous diluent addition, refrigeration stability, reconstitution concentration, and device compatibility (e.g., 50–53, 86–87, 89).

References

[1] United States Patent 6,506,405 (claim set provided in user prompt).